Open AccessDural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab
Author(s) -
Alaattin Özen,
İrfan Çiçin,
Atakan Sezer,
Sernaz Uzunoğlu,
Mert Saynak,
Hakan Gençhellaç,
Hakan Karagöl
Publication year - 2009
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.52791
Subject(s) - medicine , bevacizumab , discontinuation , folfiri , thrombosis , colorectal cancer , surgery , side effect (computer science) , adverse effect , cancer , irinotecan , chemotherapy , computer science , programming language
The adverse effects of regimes in cancer treatment have forced us to change to new targeted therapy options. Understanding these side effects, which can lead to discontinuation of the new therapy strategies, will allow the clinical management of these side effects and result in continuing therapies with effective medications. Bevacizumab, which is an IgG1 antibody against vascular endothelial growth factor, has side effects such as proteinuria, hypertension, venous and arterial thromboembolic events, and hemorrhage. This is the first reported case of dural sinus vein thrombosis, during the treatment with bevacizumab.